知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.021 秒)

    Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
    9.
    发明授权
    Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them 有权
    取代的4-苯基四氢异喹啉鎓，其制备方法，它们作为药物的用途，以及含有它们的药物

    公开(公告)号：US06911453B2

    公开(公告)日：2005-06-28

    申请号：US10309352

    申请日：2002-12-04

    申请人： Armin Hofmeister ,  Uwe Heinelt ,  Hans-Jochen Lang ,  Markus Bleich ,  Klaus Wirth ,  Michael Gekle

    发明人： Armin Hofmeister ,  Uwe Heinelt ,  Hans-Jochen Lang ,  Markus Bleich ,  Klaus Wirth ,  Michael Gekle

    IPC分类号： C07D217/18 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D217/00 ,  A61K31/47

    CPC分类号： C07D401/12 ,  C07D217/18 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

    摘要： The invention relates to compounds of the formula I in which R1 to R9 are as defined herein. In one embodiment, these compounds may be used as antihypertensives, for reducing or preventing ischemia-induced damage, as medicaments for surgical intervention for the treatment of ischemias of the nervous system, of stroke and of cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxative, as agent against ectoparasites, to prevent the formation of gallstones, as antiatherosclerotics, agents against late complications of diabetes, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophies and hyperplasias. In one embodiment, the compounds may be inhibitors of the cellular sodium-proton antiporter and influence serum lipoproteins and thus be used for the prophylaxis and for the regression of atherosclerotic lesions.

    摘要翻译： 本发明涉及其中R 1至R 9如本文所定义的式I化合物。 在一个实施方案中，这些化合物可以用作抗高血压药物，用于减少或预防缺血诱发的损伤，作为用于治疗神经系统缺血性卒中和脑水肿的外科手术的药物，休克，受损的呼吸驱动 用于治疗打鼾，作为缓泻剂，作为对外寄生虫剂的药剂，以防止胆结石的形成，作为抗动脉粥样硬化剂，用于治疗糖尿病晚期并发症的药物，癌症，纤维化病症，内皮功能障碍，器官肥厚和增生。 在一个实施方案中，化合物可以是细胞钠 - 质子逆转录酶的抑制剂并影响血清脂蛋白，因此用于预防动脉粥样硬化病变的消退。